Proton pump inhibitors (PPIs) are a successful class of medications accounting for $79 billion spent in the United States between 2007 and 2011.1 While many PPI indications involve limited or short-term use, it is not uncommon for patients to use them for extended periods or for clinicians to prescribe them for indications not supported by robust evidence of efficacy. While PPIs are generally safe, even rare infectious and noninfectious adverse events2 are important on a population level given their wide use.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Lee TC, McDonald EG. Deprescribing Proton Pump Inhibitors: Overcoming Resistance. JAMA Intern Med. 2020;180(4):571–573. doi:10.1001/jamainternmed.2020.0040
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: